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SUMMARY 
 
Purpose: Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction. 
Previous analyses of results from a prospective, observational study assessing vigabatrin-induced 
visual field constriction (described below) employed a partially subjective interpretation of static 
perimetery. In an effort to affirm these previous findings through more objective, quantitative 
methodology, we now report data from a subset analysis of refractory partial epilepsy patients in 
the study who underwent Goldmann kinetic perimetry. 
Methods: Patients aged ≥8 years with refractory partial seizures were enrolled and grouped: 
those receiving vigabatrin for ≥6 months (Group I); those who had received vigabatrin for ≥6 
months and then had discontinued for ≥6 months (Group II); and those naïve to vigabatrin 
(Group III). Patients underwent static or kinetic perimetry or both every 4–6 months for ≤3 
years. For kinetic perimetry, the temporal and nasal visual fields were measured along the 
horizontal meridian with the largest (V4e, IV4e) and smallest (I2e, I1e) isopters, respectively. 
Results: Of 735 patients enrolled, 341 had Goldmann perimetry data. Of these, 258 received 
vigabatrin. Sixteen percent of vigabatrin-exposed patients had moderate visual field defects 
(30°–60° retained temporal vision), and 3% had severe defects (<30° retained temporal vision). 
Visual function questionnaire results indicated a weak correlation between visual field 
constriction severity and visual symptoms.  
Conclusions: These results affirm both an analysis of the same study based primarily on static 
perimetry and findings from cross-sectional studies. The present analysis verifies that visual field 
constriction, when it occurs, is most often mild or moderate and is not associated with symptoms 
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of abnormal visual function. The clinical decision to prescribe vigabatrin should be based on a 
benefit-risk analysis for each individual patient. 
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1. INTRODUCTION 
Vigabatrin (Sabril), a selective and irreversible γ-aminobutyric acid transaminase inhibitor 
(Ben-Menachem, 1995),  is effective as adjunctive therapy for adult patients with refractory 
complex partial seizures (Bruni et al., 2000, French et al., 1996, Guberman and Bruni, 2000, 
Sander et al., 1990) and as monotherapy for infants with infantile spasms (West syndrome) 
(Aicardi et al., 1996, Appleton et al., 1999, Chiron et al., 1990, Chiron et al., 1997, Elterman et 
al., 2001, Wohlrab et al., 1998). Vigabatrin has been approved for these indications in the United 
States since 2009, and in many other countries since 1989. Despite its proven efficacy, the use of 
vigabatrin has been limited by the associated risk of retinopathy, characterized by irreversible, 
bilateral constriction of the visual fields, an adverse reaction to the drug first reported in 1997 
(Eke et al., 1997). Since then, several reports have described this very specific visual field defect 
in vigabatrin-treated patients (Baulac et al., 1998, Harding, 1998, Kalviainen and Nousiainen, 
2001, Lawden et al., 1999, Nicolson et al., 2002, Wild et al., 1999, Wilson and Brodie, 1997), 
and systematic retrospective (Besch et al., 2002, Hardus et al., 2000, Kalviainen and Nousiainen, 
2001, Kalviainen et al., 1999, Newman et al., 2002, Nicolson et al., 2002, Stefan et al., 2000, 
Vanhatalo et al., 2002, Wild et al., 1999) and prospective (Schmitz et al., 2002) analyses have 
suggested that it may occur in a significant number of treated patients (reported range, 14%-
92%). This large range is influenced by differing visual field testing methods, as well as the 
criteria defining abnormal fields. The visual field defect generally is asymptomatic (Wild et al., 
1999), possibly a result of, in part, the relative sparing of the central retina. However, there is 
electrophysiologic evidence, using multifocal electroretinography, that vigabatrin causes a 
reduction in function within the central retina. Other studies have reported mild decreases in 
6 
 
color vision (Johnson et al., 2000) and  reductions in grating acuity in children (Durbin et al., 
2009). 
 
In response to concerns of the European Medicines Agency, Sanofi-Aventis, the manufacturer of 
vigabatrin outside of North America, conducted a large cross-sectional study (Study 4020) with a 
prospective follow-up to further investigate vigabatrin-induced visual field constriction in 
pediatric and adult patients being treated for partial epilepsy. The study was designed to assess 
the frequency of the vigabatrin-induced visual field constriction, better characterize the 
functional consequences of the visual defect, and determine risk factors for its development. An 
interim analysis of this study and a partial analysis of the final data have been published. In these 
analyses, the primary outcome measure, the presence or absence of bilateral, concentric, 
peripheral constriction (BCPC) of the visual fields, was based on a global assessment of the 
perimetry data for each patient through partially specified criteria and predominantly static 
perimetry. The analysis of the final data set found that, among 524 evaluable patients with 1 or 
more conclusive perimetry examinations, the frequency of BCPC at the last conclusive 
examination was greatest for patients receiving vigabatrin at study entry: 26.3% for patients aged 
8–12 years and 43.3% for patients aged >12 years (Wild et al., 2009). For patients who had 
discontinued vigabatrin for ≥6 months, the frequencies were 14.9% for children and 24.5% for 
adults. Further, this report found that the risk of developing BCPC was correlated significantly 
with duration of vigabatrin therapy, mean daily dosage, and male sex. Among 386 vigabatrin-
exposed patients, visual field loss was graded mild for 15.8%, moderate for 10.6%, and severe 
for 3.9%, based on a complex grading system applied to data from both static and kinetic 
perimetry. Moreover, no relationship was found between the presence of symptoms of visual 
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difficulties ascertained by questionnaire and vigabatrin-induced visual field constriction (Wild et 
al., 2009). 
 
While for many patients, static perimetry has very low test/retest variability, for other patients, 
the rigor of the testing procedures, combined with possible fatigue and decreased cognitive 
function, produces high coefficients of variability. Because of the subjective nature of static 
perimetery for some patients, we sought to verify the findings of the previous research by 
conducting objective and quantitative analyses to affirm the rates and severity of vigabatrin-
induced visual field constriction previously observed. Through the present analyses, we provide 
the results for a subset of 341 patients in Study 4020 who underwent Goldmann kinetic 
perimetry.  
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2. METHODS 
2.1 Study Design 
This was an open-label, multicenter, comparative study conducted at 46 sites in France, South 
Korea, Italy, Spain, and Australia. Male and female patients ≥8 years of age with refractory 
partial seizures for ≥1 year were eligible. Patients were classified into 6 groups defined by 2 age 
groups and 3 treatment groups (Table 1). Children were 8–12 years of age, and adults were >12 
years. Group I was composed of patients who were receiving vigabatrin at study entry and who 
had been treated with vigabatrin as either monotherapy or polytherapy for ≥6 months before 
study entry. Group II included patients who were treated with other antiepileptic drugs (AEDs) 
for ≥6 months but who had previously received vigabatrin for ≥6 months and had discontinued 
vigabatrin ≥6 months prior to study entry. Patients in Group III were treated with other AEDs 
and had never received vigabatrin. However, these patients were permitted to initiate treatment 
with vigabatrin during the study. Patients with identified primary ophthalmologic pathology were 
excluded. All patients, or their caregivers, provided written informed consent. 
 
This study consisted of an initial screening/randomization phase, baseline visit, and a follow-up 
phase of up to 36 months. The baseline ophthalmologic assessments included ocular history and 
symptoms, listing of all ocular medications taken during the past 6 months, eye color, visual 
acuity, manifest refraction, slit-lamp biomicroscopy, intraocular pressure, bilateral dilated 
ophthalmoscopy, gonioscopy, perimetry, determination of whether any ocular findings might 
explain abnormal visual field results, and visual disability as assessed by a questionnaire. 
Perimetry (static, kinetic, or both) was repeated every 4–6 months at each follow-up visit. Sites 
were allowed to choose the perimetry device and protocol employed within broad parameters. A 
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site did not necessarily employ a consistent methodology, even for different visits of an 
individual patient.  
 
A subset of patients underwent kinetic perimetry testing — the vast majority via the Goldmann 
perimeter and the balance through the Moniteur device. The data from Goldmann perimetry were 
subjected to post-hoc analysis. Digital files of scanned perimetry records from these tests were 
submitted to an independent contract research organization (ORA Clinical Research and 
Development, Andover, MA, USA), which measured the extent of the visual fields along the 
horizontal meridian while blinded to treatment group. Measurements were conducted for the 
largest isopter tested in the temporal field and the smallest isopter tested in the nasal field. The 
majority of the data available were from the V4e and IV4e temporal isopters and the I2e and I1e 
nasal isopters. Because of non-uniformity between or within sites regarding the isopters tested, 
the data are presented in 2 ways. First, the measurements for the largest temporal and smallest 
nasal isopters tested were combined to generate summary data representing all the observations. 
Second, as a way of guarding against misleading results from combining disparate 
measurements, the measurements were analyzed separately for the 2 temporal and 2 nasal 
isopters with the most data. 
 
At each study visit, patients completed a 19-item visual function questionnaire, primarily 
consisting of questions concerning peripheral vision (eg, do you bump into doors, do you have 
trouble catching a ball). 
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2.2 Treatment 
The dosage and regimen of vigabatrin were not protocol-determined, with the exception of 7 
patients in Group III who were prescribed vigabatrin after enrollment. For these patients, the 
daily starting dosages were 1 g/day for adults and 40 mg/kg for children, and these dosages could 
be titrated up to 2–3 g/day for adults and 80–100 mg/kg for children. All other patients were 
allowed to continue the AED treatment they were receiving at study entry, with dosage 
adjustments as deemed necessary by their physicians.  
 
2.3 Data Analysis  
Measurements employed in the analyses of the largest temporal and smallest nasal isopters were 
from the last perimetry obtained for each patient during the study. For an individual isopter, the 
data were from the last perimetry obtained with that isopter, which was not necessarily the final 
perimetry obtained during the study. 
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3. RESULTS 
3.1 Patients  
A total of 735 patients enrolled in the study (Figure 1). Measurements of extent of visual fields 
based on kinetic perimetry were obtained for 359 patients. Of these 359, 341 had undergone 
Goldmann perimetry and 18 had completed perimetry with the Moniteur device. Of the 341 
patients who completed Goldmann perimetry, 258 were exposed to vigabatrin and 83 were naive 
to the drug. The distribution of these patients by treatment and age groups is shown in Table 1, 
and baseline characteristics are provided in Table 2. Distribution by sex was approximately equal 
in adults, but there was a male preponderance among children. Mean age at study entry was 10.3 
years for children and 33.1 years for adults. At study entry, the median duration of vigabatrin 
treatment was 4.1 years for both children and adults in Group I, and 1.6 years for children and 
2.5 years for adults in Group II. For children and adults in Groups I and II, mean time from first 
vigabatrin dose to first perimetry examination ranged from 4.0 to 5.7 years. Most baseline 
characteristics of patients in Group III were similar to those of patients treated with vigabatrin, 
except that patients in Group III had shorter AED exposure times than those in either Group I or 
Group II. Moreover, the subset of patients who had undergone kinetic perimetry generally was 
representative of the entire group of patients in the study. However, in this subset, the median 
durations of vigabatrin exposure were shorter for adults in Group I (3.5 vs. 4.6 years) and 
children in Group II (1.6 vs. 3.0 years). 
 
3.2 Perimetry 
The extent of visual field impairment was analyzed for the subset of 341 patients who had 
completed Goldmann perimetry. All patients had data for the temporal field, and all but 2 had 
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data for the nasal field. Based on combined data for the largest isopter tested, monocular 
temporal field at final Goldmann perimetry for the 258 vigabatrin-exposed patients ranged from 
13° to 90°, and averaged 71.1°±14.7° (Table 3 and Figure 2a). When analyzed for the V4e and 
IV4e isopters, for which the most data were available, the mean retained temporal fields for 
vigabatrin-exposed patients were 73.5° ±15.3° (range, 12°–90°) and 69.1°±15.4° (range, 7°–90°), 
respectively. 
 
Monocular nasal fields of vigabatrin-exposed patients, based on the smallest isopter tested, 
ranged from 0° to 64°, averaging 19.7°±10.8° (Table 3 and Figure 2b). When analyzed for the 
I2e and I1e isopters, for which the most data were available, the mean retained nasal fields were 
19.0°±8.3° (range, 4°–37°) and 13.2°±7.1° (range, 3°–36°), respectively. 
 
The perimetry results from vigabatrin-exposed and vigabatrin-naïve patients exhibited modest 
differences. Depending on the isopters compared, the mean retained temporal field was between 
6.9° and 8.9°greater for vigabatrin-naïve patients, while the difference in mean retained nasal 
field varied between 1.8° and 2.4° (Table 3). Cumulative frequency distribution of retained 
visual field from the combined isopter data demonstrates modest differences between the 
vigabatrin-exposed and vigabatrin-naïve patients (Figure 2).  
 
The retained temporal fields were classified as normal (>80° retained field, averaged for the 2 
eyes), mildly impaired (60°–80°), moderately impaired (30°–<60°), and severely impaired 
(<30°). The distributions of temporal visual field impairment at the last kinetic perimetry 
examination for the largest isopter tested for vigabatrin-exposed and vigabatrin-naïve patients are 
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shown in Figures 3a and 3b, respectively. Of vigabatrin-exposed patients, the majority were 
unimpaired or had mild or moderate impairment of temporal visual fields, while 2% had severe 
impairment. Another approach employed data for vigabatrin-naïve patients to calculate the 
retained visual field measurements representing the fifth, tenth, and twenty-fifth percentiles and 
applied those percentile ranges to the vigabatrin-exposed patients. By these criteria, for the 
temporal field results of the largest isopters tested, 20.2% of vigabatrin-exposed patients were 
within the fifth percentile (61.5°), 28.7% were within the tenth percentile (65.5°), and 41.5% 
were within the twenty-fifth percentile (71.5°). 
 
3.3 Visual Symptoms 
Results from the questionnaire, which assessed visual symptoms, such as bumping into objects 
and having difficulty catching a ball, showed only a weak correlation between perimetry results 
and symptoms of visual disability. When patients who had completed Goldmann perimetry were 
stratified according to the severity of visual field defect, as described in Section 3.2, we found a 
weak (r=0.16) but statistically significant (P=0.005) correlation between severity of visual field 
defect and answering “yes” to at least 1 item of the 19-item questionnaire (data not shown).  
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4. DISCUSSION 
The original study sought to estimate the prevalence and incidence of visual field defect for 
children and adults treated with vigabatrin for refractory partial epilepsy and to identify risk 
factors for their occurrence (Wild et al., 2009). It included the largest group of vigabatrin-
exposed epilepsy patients ever systematically evaluated for vision loss. The primary outcome 
measure was a qualitative determination of bilateral, concentric, peripheral constriction (BCPC) 
by a single visual field expert who was blinded to treatment group, but who had access to all 
perimetry data for each patient. Some patients underwent both static and kinetic perimetry at the 
same visit, and for those patients, the reviewer placed greater weight on static perimetry (Wild et 
al., 2009). The criteria used for determining BCPC have been described previously (Wild et al., 
1999). The advantages of this qualitative approach include consistency and the ability to 
incorporate all available perimetry data for each patient, while the disadvantages of the approach 
are a lack of objective, protocol-specified BCPC criteria and potential bias. 
 
In addition to the outcome measurement, this analysis had several limitations. First, the study 
included only 7 patients who had initiated vigabatrin therapy during the study (6 of whom had 
Goldmann perimetry and none of whom developed visual field constriction). Second, baseline 
data were not available for any of the remaining patients. Third, given that ≥6 months of 
vigabatrin exposure was required for Groups I and II and the mean exposure at enrollment was 
actually between 1.6 and 4.1 years for all groups, the earliest onset of visual field constriction 
during vigabatrin therapy could not be assessed in this study. Instead, cases of vigabatrin-
induced visual field constriction were detected only after several months or years of vigabatrin 
exposure. By contrast, a well-characterized case of visual field constriction has been reported 
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after only 4 months of vigabatrin exposure (Malmgren et al., 2001). The literature contains a 
dearth of reports of visual field testing for patients with shorter durations of drug exposure. 
Fourth, the study lacked a uniform testing method between the 46 sites or even within a single 
site. Finally, the study collected vigabatrin exposure data retrospectively. However, despite its 
limitations, this study was the largest to assess vision effects in vigabatrin-treated patients, 
providing an estimate of the frequency and severity of visual field constriction with durations of 
vigabatrin exposure between 6 months and approximately 5 years. 
 
The current paper complements the previously published analysis of this same study (Wild et al., 
2009). This analysis employed quantitative measurements of the visual field along the horizontal 
meridian from kinetic perimetry to estimate the severity of visual field defects. While this 
quantitative approach was limited by the lack of uniformity in perimetry methodology (in 
particular the failure to test the same isopters for all patients at all visits), we mitigated that 
limitation by analyzing data from individual isopters to support the findings and to summarize 
the entire data set with descriptive statistics for combined measurements of several isopters. 
 
No generally agreed upon categorization of the severity of visual field defect exists. The severity 
categories chosen for the current analysis were intended to reflect the degree of resulting 
functional limitation. For example, 120° of total width of the horizontal visual field (equivalent 
to 60° of monocular temporal vision) is the limit for having a driver’s license in many 
jurisdictions and was chosen as the dividing line between mild and moderate defect. The 
criterion of <30° for a severe deficit is similar to that chosen for several published studies based 
on kinetic perimetry. Importantly, the categories employed here are not commensurate with those 
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employed by Wild et al (Wild et al., 2009). Moreover, the duration of vigabatrin exposure was 
somewhat shorter in the subgroup of patients undergoing Goldmann perimetry than in the entire 
study population.   
 
The quantitative assessment of kinetic perimetries (Figure 3) demonstrated that the majority of 
vigabatrin-exposed patients had some constriction of the visual fields. However, this should be 
compared with the finding that 45% of vigabatrin-naïve patients also had retained temporal 
visual field <80°. The majority of vigabatrin-induced visual field defects were mild to moderate 
(Figure 3). Nevertheless, severe visual field constriction to <30° of retained monocular temporal 
visual field, corresponding to a total extent of binocular vision of <60°, occurred in 2% of 
patients. In spite of the differences between the analyses, Wild and colleagues (Wild et al., 2009) 
found that 15 of 386 patients (4%) in Groups I and II had severe vigabatrin-attributed visual field 
loss, which is similar to the findings of our present analysis. However, in contrast to the analysis 
of Wild and colleagues (Wild et al., 2009), we found a weak correlation between answering 
“yes” to at least 1 question on the visual function questionnaire and severity of the visual field 
defect.   
 
In the assessment of patients receiving vigabatrin, this analysis does not demonstrate that kinetic 
perimetry is necessarily superior to static perimetry. It is the clinician’s decision which method 
should be used for an individual patient. For some patients, (for example, those who are lethargic 
or have attention deficits), kinetic perimetry may be preferable, as it provides for more human-
to-human interaction and monitoring. On the other hand, for those are alert, cognitive intact, and 
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engaged, static perimetry may be appropriate. One size does not fit all, and judgment on patient-
by-patient basis is warranted. 
 
In conclusion, this analysis of data from the largest cross-sectional study conducted to date of 
perimetry in patients treated with vigabatrin for refractory partial epilepsy verifies that visual 
field constriction, when it occurs, is most often mild or moderate and is not associated with 
symptoms of abnormal visual function. However, for a minority of patients exposed to vigabatrin 
for months to years, the visual field constriction can be severe and symptomatic. 
The clinical decision to prescribe vigabatrin should be based on a benefit-risk analysis for each 
individual patient. Peripheral visual field constriction caused by vigabatrin is asymptomatic for 
most patients, and, thus, periodic ophthalmologic testing (including perimetry) is required to 
detect the defect. For patients with refractory complex partial epilepsy who do not experience a 
substantial improvement in seizure control after 1- to 3-month trials of vigabatrin, the drug 
should be discontinued to minimize the risk of vision loss. For patients who receive substantial 
benefit from vigabatrin, periodic ophthalmologic testing is recommended to help guide 
physicians in their ongoing benefit-risk analyses for all patients (Sergott et al., 2010). 
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TABLES 
 
Table 1. Study group based on age and treatment history (patients with Goldmann 
perimetry data) 
Patients, n  
 
 
Group 
Children  
(8–12 years) 
Adults  
(>12 years) 
I Patients currently being treated with 
vigabatrin for ≥6 months 28 92 
II Patients previously treated with 
vigabatrin for ≥6 months who had 
discontinued for ≥6 months before 
study entry 
32 100 
III Patients never treated with vigabatrin 
before study entry* 22 67 
*6 patients in Group III began receiving vigabatrin during the course of the study and 
are included in the data analyses for both the vigabatrin-exposed and vigabatrin-naïve 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.  Baseline characteristics of the study groups  
Children (n=82) Adults (n=259)  
 
 
Characteristic 
Group I 
(n=28) 
Group II 
(n=32) 
Group III 
(n=22) 
Group I 
(n=92) 
Group II 
(n=100) 
Group III 
(n=67) 
Sex, n (%) 
  Male 
  Female 
 
14 (50.0) 
14 (50.0) 
 
20 (62.5) 
12 (37.5) 
 
14 (63.6) 
8 (36.4) 
 
40 (43.5) 
52 (56.5) 
 
54 (54.0) 
46 (46.0) 
 
29 (43.3) 
38 (56.7) 
Mean age, years ±SD 10.3±1.4 10.1±1.3 10.5±1.3 33.0±15.3 33.2±14.5 33.0±14.3 
Mean duration of vigabatrin 
dosing at study entry, years 
±SD 
4.1±2.8 1.6±1.7 NA 4.1±2.6 2.5±2.2 NA 
Mean time from first 
vigabatrin dose to first 
perimetry examination, 
years ±SD 
4.1±2.8 
(n=28) 
4.0±2.5 
(n=31) NA 
4.1±2.6 
(n=92) 
5.7±2.8 
(n=100) NA 
Mean duration of AED use, 
years ±SD 
4.4 ± 3.0 
(n=21) 
4.1 ± 3.0 
(n=32) 
3.3 ± 1.9 
(n=22) 
9.6 ± 7.6 
(n=83) 
8.8 ± 7.5 
(n=97) 
10.0 ± 10.0 
(n=67) 
AED=antiepileptic drug; NA=not applicable; SD=standard deviation. 
 
 
 
 Table 3.  Degrees of retained visual field along the horizontal meridian. 
Group Isopter n Mean Median Minimum Maximum SD 
Temporal Field 
VGB-exposed Largest 258 71.1 73.0 13.0 90.0 14.7 
 V4e 135 73.5 77.0 11.5 90.0 15.3 
 IV4e 131 69.1 72.5 7.0 90.0 15.4 
VGB-naïve Largest 83 78.9 82.0 27.0 91.0 12.3 
 V4e 40 82.4 87.3 25.0 91.0 13.9 
 IV4e 38 76.0 80.0 39.5 90.0 13.7 
Nasal Field 
VGB-exposed Smallest 256 19.7 19.0 0.0 63.5 10.8 
 I2e 86 19.0 21.3 4.0 36.5 8.3 
 I1e 157 13.2 11.5 3.0 36.0 7.1 
VGB-naïve Smallest 81 21.5 20.0 3.5 46.5 11.9 
 I2e 28 21.8 24.8 0.0 37.0 10.5 
 I1e 44 15.6 14.5 4.0 41.0 8.7 
SD=standard deviation; VGB=vigabatrin. 
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FIGURE LEGENDS  
 
Figure 1. Distribution of patients who underwent kinetic perimetry. 
 
Figure 2. Cumulative distribution of degrees in the (A) temporal visual field at final 
perimetry in vigabatrin-exposed (n=258) and vigabatrin-naïve patients (n=83) and (B) 
nasal visual field at final perimetry in vigabatrin-exposed (n=256) and vigabatrin-naïve  
(n=81) patients.  
 
Figure 3. Severity of visual field defect at last kinetic perimetry in (A) vigabatrin-exposed 
and (B) vigabatrin-naïve patients. Unimpaired: >80° monocular temporal field retained; Mild: 
60°–80° monocular temporal field retained; Moderate: 30°–60° monocular temporal field 
retained; Severe: <30° monocular temporal field retained. Measurements are of largest isopter 
tested at final Goldmann perimetry. 
 
